NUTX — Stock Film
STOCK FILMSCENE 1/11NUTX · $189
Stock Expert AI presents
NUTX
Nutex Health, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Nutex Health, Inc. A quick introduction.

On the stock market since 2022, it operates in the world of health and science. It has 1,005 employees. Now — the numbers.

on the stock market since 2022
1,005 employees
$1.3B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $8 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 8%

This is an established company with proven profits.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 27% a year over the last 4 years. Red columns mark years that ended in a loss.

$331.5M
2021
$219.3M
2022
$247.6M
2023
$479.9M
2024
$875.3M
2025
What executives did with their own stock over the last 12 months:
35 buy6 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
97
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
52
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
92
very strong

The price looks reasonable next to what the company earns.

GROWTH
89
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
90
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Sales are growing fast8/10
Fat profit on each sale8/10
WEAK SPOTS
Heavy bets against the stock4/10
WORTH WATCHING

Bets Against the Stock: The number of investors betting on a fall stands out.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 59% a year on average.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 35 buys and 6 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $31064% above today’s price.

1
THE RISKS · 1/1
Heavy bets against the stock

The weight of investors positioned for a fall can be felt in the market. Council score: 4/10.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, NUTX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: NUTX is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film